
Daniel E. Kolker
Examiner (ID: 8774)
| Most Active Art Unit | 1649 |
| Art Unit(s) | 1649, 1646, 1644, 1645 |
| Total Applications | 546 |
| Issued Applications | 177 |
| Pending Applications | 78 |
| Abandoned Applications | 291 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 7467612
[patent_doc_number] => 20040120891
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2004-06-24
[patent_title] => 'Compounds for intracellular delivery of therapeutic moieties to nerve cells'
[patent_app_type] => new
[patent_app_number] => 10/655756
[patent_app_country] => US
[patent_app_date] => 2003-09-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11942
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 6
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0120/20040120891.pdf
[firstpage_image] =>[orig_patent_app_number] => 10655756
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/655756 | Compounds for intracellular delivery of therapeutic moieties to nerve cells | Sep 4, 2003 | Abandoned |
Array
(
[id] => 7134667
[patent_doc_number] => 20040043410
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2004-03-04
[patent_title] => 'Methods for testing for and inhibiting the development of Huntington\'s disease'
[patent_app_type] => new
[patent_app_number] => 10/654850
[patent_app_country] => US
[patent_app_date] => 2003-09-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3198
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 73
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0043/20040043410.pdf
[firstpage_image] =>[orig_patent_app_number] => 10654850
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/654850 | Methods for testing for and inhibiting the development of Huntington's disease | Sep 3, 2003 | Abandoned |
Array
(
[id] => 7349313
[patent_doc_number] => 20040047865
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2004-03-11
[patent_title] => 'Compositions and their uses'
[patent_app_type] => new
[patent_app_number] => 10/655405
[patent_app_country] => US
[patent_app_date] => 2003-09-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 6530
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 13
[patent_words_short_claim] => 14
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0047/20040047865.pdf
[firstpage_image] =>[orig_patent_app_number] => 10655405
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/655405 | Compositions and their uses | Sep 3, 2003 | Abandoned |
Array
(
[id] => 170764
[patent_doc_number] => 07662780
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2010-02-16
[patent_title] => 'Administering hypocretin to obese individuals'
[patent_app_type] => utility
[patent_app_number] => 10/526110
[patent_app_country] => US
[patent_app_date] => 2003-08-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 3
[patent_no_of_words] => 17817
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 44
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/07/662/07662780.pdf
[firstpage_image] =>[orig_patent_app_number] => 10526110
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/526110 | Administering hypocretin to obese individuals | Aug 26, 2003 | Issued |
| 09/194619 | Methods and compositions for development of drug screening procedures and diagnostic tools | Aug 24, 2003 | Abandoned |
Array
(
[id] => 7677187
[patent_doc_number] => 20040152639
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2004-08-05
[patent_title] => 'Non-mammalian GnRH analogs and uses thereof in regulation of fertility and pregnancy'
[patent_app_type] => new
[patent_app_number] => 10/639405
[patent_app_country] => US
[patent_app_date] => 2003-08-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 40
[patent_figures_cnt] => 40
[patent_no_of_words] => 27369
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0152/20040152639.pdf
[firstpage_image] =>[orig_patent_app_number] => 10639405
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/639405 | Non-mammalian GnRH analogs and uses thereof in regulation of fertility and pregnancy | Aug 11, 2003 | Abandoned |
| 10/639749 | Non-mammalian GnRH analogs and uses thereof in regulation of fertility and pregnancy | Aug 11, 2003 | Abandoned |
Array
(
[id] => 7069447
[patent_doc_number] => 20050244832
[patent_country] => US
[patent_kind] => A9
[patent_issue_date] => 2005-11-03
[patent_title] => 'Class II cytokine receptor-7'
[patent_app_type] => utility
[patent_app_number] => 10/636716
[patent_app_country] => US
[patent_app_date] => 2003-08-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13107
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A9/0244/20050244832.pdf
[firstpage_image] =>[orig_patent_app_number] => 10636716
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/636716 | Class II cytokine receptor-7 | Aug 6, 2003 | Abandoned |
Array
(
[id] => 7069447
[patent_doc_number] => 20050244832
[patent_country] => US
[patent_kind] => A9
[patent_issue_date] => 2005-11-03
[patent_title] => 'Class II cytokine receptor-7'
[patent_app_type] => utility
[patent_app_number] => 10/636716
[patent_app_country] => US
[patent_app_date] => 2003-08-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13107
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A9/0244/20050244832.pdf
[firstpage_image] =>[orig_patent_app_number] => 10636716
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/636716 | Class II cytokine receptor-7 | Aug 6, 2003 | Abandoned |
Array
(
[id] => 7069447
[patent_doc_number] => 20050244832
[patent_country] => US
[patent_kind] => A9
[patent_issue_date] => 2005-11-03
[patent_title] => 'Class II cytokine receptor-7'
[patent_app_type] => utility
[patent_app_number] => 10/636716
[patent_app_country] => US
[patent_app_date] => 2003-08-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13107
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A9/0244/20050244832.pdf
[firstpage_image] =>[orig_patent_app_number] => 10636716
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/636716 | Polynucleotides encoding a class II cytokine receptor | Aug 6, 2003 | Abandoned |
Array
(
[id] => 7341398
[patent_doc_number] => 20040191240
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2004-09-30
[patent_title] => 'Composition and method for nerve regeneration'
[patent_app_type] => new
[patent_app_number] => 10/633423
[patent_app_country] => US
[patent_app_date] => 2003-07-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 27
[patent_figures_cnt] => 27
[patent_no_of_words] => 117303
[patent_no_of_claims] => 262
[patent_no_of_ind_claims] => 35
[patent_words_short_claim] => 10
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0191/20040191240.pdf
[firstpage_image] =>[orig_patent_app_number] => 10633423
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/633423 | Composition and method for nerve regeneration | Jul 30, 2003 | Abandoned |
Array
(
[id] => 7348443
[patent_doc_number] => 20040248252
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2004-12-09
[patent_title] => 'DNAs encoding mammalian histamine receptor of the H4 subtype'
[patent_app_type] => new
[patent_app_number] => 10/626445
[patent_app_country] => US
[patent_app_date] => 2003-07-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 14
[patent_no_of_words] => 15919
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 3
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0248/20040248252.pdf
[firstpage_image] =>[orig_patent_app_number] => 10626445
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/626445 | DNAs encoding mammalian histamine receptor of the H4 subtype and encoded protein | Jul 22, 2003 | Issued |
Array
(
[id] => 7470822
[patent_doc_number] => 20040096877
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2004-05-20
[patent_title] => 'Novel proteins and nucleic acids encoding same'
[patent_app_type] => new
[patent_app_number] => 10/624932
[patent_app_country] => US
[patent_app_date] => 2003-07-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 72749
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 10
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0096/20040096877.pdf
[firstpage_image] =>[orig_patent_app_number] => 10624932
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/624932 | Novel proteins and nucleic acids encoding same | Jul 20, 2003 | Abandoned |
Array
(
[id] => 7471068
[patent_doc_number] => 20040096913
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2004-05-20
[patent_title] => 'Cloning and expression of a new MCP receptor in glial cells'
[patent_app_type] => new
[patent_app_number] => 10/623472
[patent_app_country] => US
[patent_app_date] => 2003-07-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 13
[patent_no_of_words] => 9360
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 6
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0096/20040096913.pdf
[firstpage_image] =>[orig_patent_app_number] => 10623472
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/623472 | Cloning and expression of a new MCP receptor in glial cells | Jul 17, 2003 | Abandoned |
Array
(
[id] => 7463706
[patent_doc_number] => 20040101521
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2004-05-27
[patent_title] => 'Iron sequestration or elimination to reduce neurodegeneration or Parkinsons disease progression'
[patent_app_type] => new
[patent_app_number] => 10/618444
[patent_app_country] => US
[patent_app_date] => 2003-07-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 10
[patent_no_of_words] => 14544
[patent_no_of_claims] => 93
[patent_no_of_ind_claims] => 8
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0101/20040101521.pdf
[firstpage_image] =>[orig_patent_app_number] => 10618444
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/618444 | Iron sequestration or elimination to reduce neurodegeneration or Parkinsons disease progression | Jul 10, 2003 | Abandoned |
Array
(
[id] => 7466042
[patent_doc_number] => 20040198658
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2004-10-07
[patent_title] => 'Stanniocalcin polynucleotides, polypeptides and methods based thereon'
[patent_app_type] => new
[patent_app_number] => 10/614990
[patent_app_country] => US
[patent_app_date] => 2003-07-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 12
[patent_no_of_words] => 88274
[patent_no_of_claims] => 31
[patent_no_of_ind_claims] => 15
[patent_words_short_claim] => 3
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0198/20040198658.pdf
[firstpage_image] =>[orig_patent_app_number] => 10614990
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/614990 | Stanniocalcin polynucleotides, polypeptides and methods based thereon | Jul 8, 2003 | Abandoned |
Array
(
[id] => 7155766
[patent_doc_number] => 20050026823
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2005-02-03
[patent_title] => 'Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues'
[patent_app_type] => utility
[patent_app_number] => 10/600862
[patent_app_country] => US
[patent_app_date] => 2003-06-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 20
[patent_figures_cnt] => 20
[patent_no_of_words] => 30322
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 6
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0026/20050026823.pdf
[firstpage_image] =>[orig_patent_app_number] => 10600862
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/600862 | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues | Jun 19, 2003 | Abandoned |
Array
(
[id] => 797903
[patent_doc_number] => 07427489
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2008-09-23
[patent_title] => 'Screening assay to identify modulators of the sleep/wake cycle'
[patent_app_type] => utility
[patent_app_number] => 10/464817
[patent_app_country] => US
[patent_app_date] => 2003-06-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30446
[patent_no_of_claims] => 33
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 170
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/07/427/07427489.pdf
[firstpage_image] =>[orig_patent_app_number] => 10464817
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/464817 | Screening assay to identify modulators of the sleep/wake cycle | Jun 16, 2003 | Issued |
Array
(
[id] => 5726350
[patent_doc_number] => 20060057110
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2006-03-16
[patent_title] => 'Antigen-presenting cells for neuroprotection and nerve regeneration'
[patent_app_type] => utility
[patent_app_number] => 10/517666
[patent_app_country] => US
[patent_app_date] => 2003-06-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 12
[patent_no_of_words] => 16557
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 6
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0057/20060057110.pdf
[firstpage_image] =>[orig_patent_app_number] => 10517666
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/517666 | Antigen-presenting cells for neuroprotection and nerve regeneration | Jun 11, 2003 | Abandoned |
Array
(
[id] => 5814790
[patent_doc_number] => 20060084597
[patent_country] => US
[patent_kind] => A2
[patent_issue_date] => 2006-04-20
[patent_title] => 'USE OF COMPOUNDS HAVING GIP ACTIVITY FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH ABNORMAL LOSS OF CELLS AND/OR FOR THE TREATMENT OF OBESITY'
[patent_app_type] => utility
[patent_app_number] => 10/518159
[patent_app_country] => US
[patent_app_date] => 2005-01-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 14594
[patent_no_of_claims] => 65
[patent_no_of_ind_claims] => 13
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A2/0084/20060084597.pdf
[firstpage_image] =>[orig_patent_app_number] => 10518159
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/518159 | Use of compounds having gip activity for the treatment of disorders associated with abnormal loss of cells and/or for the treatment of obesity | Jun 10, 2003 | Abandoned |